$AKBA at .39 way undervalued Japan sales doubled and projected to triple next year. Rev from currently approved drug. Should get Approved for EU Q1 2023 ARDS should be good from UT health / DOD grant Partnership should come any day with Japan Sales booming. Hello under .40 Cents is a no brainer $XBI $SPY $LABU
3
7
7 Likes